Patient-specific tumor-associated antigens and neoantigens presented on tumor membrane vesicles

Patient-specific tumor-associated antigens (TAAs) and neoantigens presented on tumor membrane vesicles (TMVs) represent a sophisticated class of personalized cancer immunotherapy targets. TMVs, which include exosomes and microvesicles, are naturally occurring lipid-bilayer particles secreted by malignant cells that encapsulate a snapshot of the tumor's proteome, including unique somatic mutations (neoantigens) and overexpressed self-antigens (TAAs) (Source: Nature Reviews Cancer, 2020). These vesicles are highly immunogenic because they present antigens in their native membrane-bound conformation, often alongside endogenous danger signals like heat shock proteins (HSPs) that act as natural adjuvants (Source: Journal of Extracellular Vesicles, 2021). In a therapeutic context, TMVs are isolated from a patient's biopsy, purified, and used as a vaccine to prime the immune system to recognize the specific antigenic signature of that individual's cancer. This approach facilitates the activation of both CD4+ and CD8+ T cells through professional antigen-presenting cells, such as dendritic cells, which internalize the vesicles and cross-present the contained antigens (Source: Frontiers in Immunology, 2022). By targeting a broad spectrum of patient-specific antigens simultaneously, TMV-based therapies aim to overcome the challenges of tumor heterogeneity and immune evasion that often limit single-antigen vaccines.

Other names

Tumor-derived extracellular vesiclesTEVsTumor-derived exosomesTEXPersonalized tumor-derived vesicle vaccinesNeoantigen-bearing tumor vesicles

Induction of a multi-antigenic, patient-specific T-cell response via the delivery of membrane-bound tumor antigens to professional antigen-presenting cells for cross-presentation.